clonidine has been researched along with Ataxia in 3 studies
Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.
clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.
Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Male albino rats given a bilateral injection of Baclofen (Lioresal) (12 micrograms/rat) in the cerebral ventricles showed a behavioral syndrome of activation + ataxia, paddling, tail-pinch hyperresponse and anesthesia." | 3.66 | The role of monoamines for the central effects of Baclofen on behavior of rats. ( Smith, DF; Vestergaard, P, 1979) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (66.67) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harkin, A | 1 |
| Morris, K | 1 |
| Kelly, JP | 1 |
| O'Donnell, JM | 1 |
| Leonard, BE | 1 |
| Smith, DF | 1 |
| Vestergaard, P | 1 |
| Luttinger, D | 1 |
| Ferrari, R | 1 |
| Perrone, MH | 1 |
| Haubrich, DR | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Guanfacine for PONV and Pain After Sinus Surgery[NCT02882854] | 84 participants (Actual) | Interventional | 2016-11-30 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes
| Intervention | minutes (Median) |
|---|---|
| Guanfacine | 128 |
| Placebo | 110 |
PONV assessed using nVRS at 24 hours postop when 0 is no nausea and 10 is worst nausea. (NCT02882854)
Timeframe: 24 hours post op
| Intervention | score on a scale (Median) |
|---|---|
| Guanfacine | 0.00 |
| Placebo | 0.00 |
Postoperative pain assessment using VAS at 24 hours postop when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 24 hours postop
| Intervention | score on a scale (Median) |
|---|---|
| Guanfacine | 3 |
| Placebo | 2 |
Total narcotic requirement in PACU tallied in morphine equivalents during PACU stay (NCT02882854)
Timeframe: Time frame between arrival and discharge in PACU, approximately 90 minutes
| Intervention | morphine equivalents (Median) |
|---|---|
| Guanfacine | 8.75 |
| Placebo | 7.50 |
Maximum postoperative pain assessment assessed in PACU at 15, 30 and 60 minutes after PACU arrival using VAS when 0 is no pain and 10 is worst pain (NCT02882854)
Timeframe: 15, 30, 60 minutes after arriving in PACU
| Intervention | Participants (Count of Participants) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 15 minutes after PACU admission72482977 | 15 minutes after PACU admission72482978 | 30 minutes after PACU admission72482977 | 30 minutes after PACU admission72482978 | 60 minutes after PACU admission72482977 | 60 minutes after PACU admission72482978 | |||||||||||||
| Mild (Pain nVRS 1-5) | Moderate/Severe (Pain nVRS 6-10) | None (Pain nVRS 0) | ||||||||||||||||
| Guanfacine | 31 | |||||||||||||||||
| Placebo | 24 | |||||||||||||||||
| Guanfacine | 0 | |||||||||||||||||
| Placebo | 5 | |||||||||||||||||
| Guanfacine | 8 | |||||||||||||||||
| Placebo | 10 | |||||||||||||||||
| Guanfacine | 18 | |||||||||||||||||
| Placebo | 20 | |||||||||||||||||
| Guanfacine | 7 | |||||||||||||||||
| Placebo | 6 | |||||||||||||||||
| Guanfacine | 14 | |||||||||||||||||
| Placebo | 14 | |||||||||||||||||
| Guanfacine | 12 | |||||||||||||||||
| Placebo | 16 | |||||||||||||||||
| Guanfacine | 6 | |||||||||||||||||
| Placebo | 13 | |||||||||||||||||
| Guanfacine | 21 | |||||||||||||||||
| Placebo | 12 | |||||||||||||||||
3 other studies available for clonidine and Ataxia
| Article | Year |
|---|---|
Modulation of MK-801-induced behaviour by noradrenergic agents in mice.
Topics: Adrenergic Agents; Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Adrenergic Uptake Inhibi | 2001 |
The role of monoamines for the central effects of Baclofen on behavior of rats.
Topics: Anesthesia; Animals; Ataxia; Baclofen; Catecholamines; Clonidine; Dopamine; Injections, Intraventric | 1979 |
Pharmacological analysis of alpha-2 adrenergic mechanisms in nociception and ataxia.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Ataxia; Binding, Competitive; Brai | 1985 |